Default company panoramic image
Xortx logo 700x700

XORTX Pharma Corp.

Treating orphan and lifestyle diseases, uric acid metabolism causes health risks.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Calgary, AB, Canada
  • Currency USD
  • Founded July 2012
  • Employees 4
  • Website xortx.com

Company Summary

XORTX Pharma Corp is a drug development company focused on orphan diseases that have a uric acid (UA) imbalance. High UA is an independent risk factor for autosomal dominant polycystic kidney disease (ADPKD) progression. XORTX is developing oxypurinol to decrease UA and treat progressive kidney disease. Phase II trial successes show strong safe and effectiveness. Our business model is to complete phase II PoC in ADPKD then license.

Team

  • Default avatar
    Allen Davidoff
    president

    Dr. Allen W. Davidoff, Ph.D. Most recently acted as Chief Scientific officer of Stem Cell Therapeutics Corp. Overall, 10 years of drug development experience with a broad clinical and regulatory experience. Senior management experience in pharmaceutical R&D including 2 investigational new drug ("IND") applications or supplemental IND's, 2 phase I studies (4 multi-country), 7 phase II studies, and 1 new drug applications. Including 2 years as Sen

  • Default avatar
    Grace Jung
    Director Manufacturing & Synthetic Chemistry

    Grace Jung, PhD (21 years of experience in drug discovery and development) was formerly Senior Director of Research (Chemistry) at Cardiome. During the 14 years at Cardiome, she led the chemistry team in the discovery of antiarrhythmic vernakalant and in process research efforts to devise a scalable manufacturing route for vernakalant. Before joining Cardiome, Grace spent 7 years at Boehringer Ingelheim (Laval, QC, Canada), where she was a medici

  • Default avatar
    Brian Mangal
    Director Business Development

    Brian Mangal, M.Sc. (12 years of clinical development experience), Formerly Director Biostatistics at Cardiome. Clinical development experience includes design, analysis and reporting of over 50 clinical trials, three FDA submissions, one TPD submission, a successful EMEA submission and numerous interactions with regulatory authorities, including participation in a successful advisory panel meeting for Vernakalant.  

  • Default avatar
    Alan Moore
    Clinical & Regulatory Affairs

    Dr. Alan F. Moore, Ph.D. He has extensive clinical development experience and 23 years of senior management experience in pharmaceutical R&D with P&G during his esteemed career, he has completed 11 investigational new drug ("IND") applications or supplemental IND's, 15 phase I studies, 12 phase II studies, 7 phase III studies and 2 new drug applications. Most recently CEO of BetaStem Inc.

Advisors

  • Default avatar
    Dr. Richard Johnson
    Clinical Advisory Board Member
    Unconfirmed
    1c9dfe10 cca5 4420 9488 131a5a4b0484
    Advisory

Previous Investors

  • Default avatar
    Friends and Family - seed capital
    Unconfirmed